|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-1.95% | -8.87% |
| 10/11/23 | Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar | MT |
| 25/07/23 | Xbrane Biopharma and Stada consider options for ranibizumab | FW |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 31/08/2018 | |
Boris Döbler
DFI | Director of Finance/CFO | - | 31/12/2022 |
Miguel Fernandez
CTO | Chief Tech/Sci/R&D Officer | 61 | 31/12/2014 |
| Director | Title | Age | Since |
|---|---|---|---|
Jens Steegers
BRD | Director/Board Member | 46 | 03/06/2014 |
Eric Cornut
BRD | Director/Board Member | 69 | 25/08/2016 |
Günter von Au
CHM | Chairman | 75 | 26/09/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -1.95% | - | - | 5.73B | ||
| -0.90% | -0.15% | +14.11% | +81.10% | 48.15B | ||
| -0.23% | -1.65% | +67.15% | +112.03% | 35.59B | ||
| -0.76% | -1.44% | -4.29% | +37.63% | 11.9B | ||
| -0.88% | -0.62% | +17.31% | +89.97% | 11.85B | ||
| +0.19% | +2.87% | +34.92% | +139.73% | 9.31B | ||
| +3.37% | -0.10% | +51.64% | -3.75% | 7.02B | ||
| -0.75% | -0.91% | +17.45% | +37.70% | 6.91B | ||
| -2.25% | -2.08% | +0.45% | +209.99% | 6.55B | ||
| -9.93% | +0.35% | -31.51% | +16.58% | 6.13B | ||
| Average | -1.21% | -0.14% | +18.58% | +80.11% | 14.91B | |
| Weighted average by Cap. | -0.85% | -0.48% | +26.79% | +86.59% |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- SAZ Stock
Select your edition
All financial news and data tailored to specific country editions
















